Literature DB >> 12072520

RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy.

Anne-Kathrin Zaiss1, Sodany Son, Lung-Ji Chang.   

Abstract

The expression of reporter genes driven by the same human elongation factor 1alpha (EF1alpha) promoter in murine leukemia virus (MLV)- and human immunodeficiency virus type 1 (HIV-1)-based vectors was studied in either transfected or virally transduced cells. The HIV-1 vectors consistently expressed 3 to 10 times higher activity than the MLV vectors at both the RNA and protein levels. The difference was not attributable to transcriptional interference, alternative enhancer/silencer, or differential EF1alpha intron splicing. Based on nuclear run-on assays, both vectors exhibited similar EF1alpha transcriptional activity. The reduced RNA levels of MLV vectors could not be explained by the decrease in RNA half-lives. Southern analysis of proviral DNA indicated that both HIV-1 and MLV vectors efficiently propagated the EF1alpha intron in the transduced cells. To decipher the discrepancy in transgene expression between MLV and HIV-1 vectors, the role of RNA 3'-end processing was examined using a sensitive Cre/lox reporter assay. The results showed that MLV vectors, but not HIV-1 vectors, displayed high frequencies of readthrough of the 3' polyadenylation signal. Interestingly, the polyadenylation signal of a self-inactivating (SIN) HIV-1 vector was as leaky as that of the MLV vectors, suggesting a potential risk of oncogene activation by the lentiviral SIN vectors. Together, our results suggest that an efficient polyadenylation signal would improve both the efficacy and the safety of these vectors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072520      PMCID: PMC136337          DOI: 10.1128/jvi.76.14.7209-7219.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  The 3' untranslated region of messenger RNA: A molecular 'hotspot' for pathology?

Authors:  B Conne; A Stutz; J D Vassalli
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

3.  High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors.

Authors:  P Salmon; V Kindler; O Ducrey; B Chapuis; R H Zubler; D Trono
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

Review 4.  Mechanism and regulation of mRNA polyadenylation.

Authors:  D F Colgan; J L Manley
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

5.  Efficient packaging of readthrough RNA in ALV: implications for oncogene transduction.

Authors:  S A Herman; J M Coffin
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

6.  The retroviruses human immunodeficiency virus type 1 and Moloney murine leukemia virus adopt radically different strategies to regulate promoter-proximal polyadenylation.

Authors:  A Furger; J Monks; N J Proudfoot
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 7.  Gene therapy: trials and tribulations.

Authors:  N Somia; I M Verma
Journal:  Nat Rev Genet       Date:  2000-11       Impact factor: 53.242

8.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

Review 9.  Lentivirus replication and regulation.

Authors:  H Tang; K L Kuhen; F Wong-Staal
Journal:  Annu Rev Genet       Date:  1999       Impact factor: 16.830

10.  The molecular genetics of lentiviral vectors--current and future perspectives.

Authors:  L J Chang; E E Gay
Journal:  Curr Gene Ther       Date:  2001-09       Impact factor: 4.391

View more
  42 in total

1.  Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Authors:  Wenqin Xu; Jill L Russ; Maribeth V Eiden
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector.

Authors:  Boris Kantor; Matthew Bayer; Hong Ma; Jude Samulski; Chengwen Li; Thomas McCown; Tal Kafri
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

3.  Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells.

Authors:  Jin He; Qing Yang; Lung-Ji Chang
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Two distinct Moloney murine leukemia virus RNAs produced from a single locus dimerize at random.

Authors:  Jessica A Flynn; Alice Telesnitsky
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

Review 5.  3' end mRNA processing: molecular mechanisms and implications for health and disease.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

Review 6.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

7.  Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element.

Authors:  Hideki Hanawa; Motoko Yamamoto; Huifen Zhao; Takashi Shimada; Derek A Persons
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

8.  Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.

Authors:  Fabrizia Urbinati; Paritha Arumugam; Tomoyasu Higashimoto; Anil Perumbeti; Kyle Mitts; Ping Xia; Punam Malik
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

9.  Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype.

Authors:  Bei Wang; Shuhong Han; Lily Lien; Lung-Ji Chang
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 10.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.